PASSAGE BIO INC. - CO
0.6210
25-November-24 16:45:01
15 minutes delayed
Stocks
+0.1160
+22.97%
Today's range
0.4709 - 0.6900
ISIN
N/A
Source
NASDAQ
-
18 May 2022 07:00:00 By Nasdaq GlobeNewswire
-
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
16 May 2022 07:00:01 By Nasdaq GlobeNewswire
-
Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022
09 May 2022 07:00:01 By Nasdaq GlobeNewswire
-
03 May 2022 14:13:24 By Nasdaq GlobeNewswire
-
02 May 2022 16:01:00 By Nasdaq GlobeNewswire
-
Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
22 Apr 2022 16:01:00 By Nasdaq GlobeNewswire
-
29 Mar 2022 07:00:01 By Nasdaq GlobeNewswire
-
Passage Bio to Participate in Upcoming Investor Conferences
28 Mar 2022 07:00:00 By Nasdaq GlobeNewswire
-
Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway
15 Mar 2022 07:00:01 By Nasdaq GlobeNewswire
-
10 Mar 2022 07:00:01 By Nasdaq GlobeNewswire
-
03 Mar 2022 07:00:01 By Nasdaq GlobeNewswire
-
Passage Bio to Participate in Upcoming March Investor Conferences
01 Mar 2022 07:00:03 By Nasdaq GlobeNewswire
-
Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022
24 Feb 2022 07:00:00 By Nasdaq GlobeNewswire
-
11 Feb 2022 11:00:00 By Nasdaq GlobeNewswire
-
31 Jan 2022 07:00:00 By Nasdaq GlobeNewswire
-
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire
-
Passage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
03 Jan 2022 07:00:00 By Nasdaq GlobeNewswire
-
17 Dec 2021 07:00:00 By Nasdaq GlobeNewswire
-
Passage Bio Announces Pipeline Expansion and Clinical Program Update
08 Dec 2021 07:00:00 By Nasdaq GlobeNewswire
-
Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
19 Nov 2021 16:00:00 By Nasdaq GlobeNewswire